Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Operating Leases (2021 - 2025)

Historic Operating Leases for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $98.5 million.

  • Roivant Sciences' Operating Leases rose 886.84% to $98.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $98.5 million, marking a year-over-year increase of 886.84%. This contributed to the annual value of $90.3 million for FY2025, which is 10063.97% up from last year.
  • Roivant Sciences' Operating Leases amounted to $98.5 million in Q4 2025, which was up 886.84% from $89.8 million recorded in Q3 2025.
  • Roivant Sciences' Operating Leases' 5-year high stood at $98.5 million during Q4 2025, with a 5-year trough of $43.2 million in Q3 2024.
  • Moreover, its 5-year median value for Operating Leases was $61.2 million (2021), whereas its average is $64.1 million.
  • As far as peak fluctuations go, Roivant Sciences' Operating Leases crashed by 1706.35% in 2022, and later soared by 10802.04% in 2025.
  • Over the past 5 years, Roivant Sciences' Operating Leases (Quarter) stood at $62.1 million in 2021, then dropped by 11.54% to $54.9 million in 2022, then decreased by 14.32% to $47.1 million in 2023, then soared by 92.27% to $90.5 million in 2024, then increased by 8.87% to $98.5 million in 2025.
  • Its Operating Leases was $98.5 million in Q4 2025, compared to $89.8 million in Q3 2025 and $90.3 million in Q2 2025.